CHRISTIE BALLANTYNE to Adolescent
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Adolescent.
Connection Strength
0.432
-
Lipoprotein(a) levels in a population with clinical atherosclerotic cardiovascular disease in the United States: A subanalysis from the Lp(a)HERITAGE study. J Clin Lipidol. 2025 Jan-Feb; 19(1):28-38.
Score: 0.067
-
Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. Am J Cardiol. 2016 Jun 15; 117(12):1928-33.
Score: 0.037
-
Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016 May-Jun; 10(3):556-67.
Score: 0.036
-
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J. 2012 Mar; 163(3):515-21, 521.e1-3.
Score: 0.028
-
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 01; 101(5):625-30.
Score: 0.021
-
Trends in Cardiovascular Disease-Related Mortality in Texas. Tex Heart Inst J. 2024 Jul-Dec; 51(2):e248426.
Score: 0.017
-
Sociodemographic, lifestyle, and medical factors associated with calculated free testosterone concentrations in men: individual participant data meta-analyses. Eur J Endocrinol. 2024 Oct 29; 191(5):523-534.
Score: 0.017
-
NLA/ASPC response to the USPSTF recommendation statement on screening lipid panel in children and adolescents. J Clin Lipidol. 2023 Sep-Oct; 17(5):559-560.
Score: 0.015
-
Factors Associated With Circulating Sex Hormones in Men : Individual Participant Data Meta-analyses. Ann Intern Med. 2023 09; 176(9):1221-1234.
Score: 0.015
-
Prevalence and Determinants of Difficulty in Accessing Medical Care in U.S. Adults. Am J Prev Med. 2021 10; 61(4):492-500.
Score: 0.013
-
Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. Popul Health Manag. 2022 02; 25(1):39-45.
Score: 0.013
-
Outcomes of Acute Myocardial Infarction in Patients with Familial Hypercholesteremia. Am J Med. 2021 08; 134(8):992-1001.e4.
Score: 0.013
-
Temporal Trends in E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016 to 2018. Am J Med. 2020 09; 133(9):e508-e511.
Score: 0.012
-
Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. Nat Commun. 2019 Nov 12; 10(1):5121.
Score: 0.012
-
Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. Am J Epidemiol. 2019 Jun 01; 188(6):1033-1054.
Score: 0.011
-
Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. Nat Genet. 2019 Apr; 51(4):636-648.
Score: 0.011
-
Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clin J Am Soc Nephrol. 2018 12 07; 13(12):1842-1850.
Score: 0.011
-
Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. Am J Hum Genet. 2018 11 01; 103(5):691-706.
Score: 0.011
-
Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol. 1998 May; 18(5):723-31.
Score: 0.011
-
Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. J Clin Lipidol. 2013 Jul-Aug; 7(4):292-303.
Score: 0.007
-
ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther. 2012 Apr; 26(2):181-7.
Score: 0.007
-
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects?on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
Score: 0.007
-
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011 Oct 29; 378(9802):1547-59.
Score: 0.007
-
Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011 Nov-Dec; 5(6):474-82.
Score: 0.007
-
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S1-8.
Score: 0.007
-
Variation in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations. Acta Diabetol. 2010 Dec; 47 Suppl 1:199-207.
Score: 0.006
-
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009 Jun 15; 103(12):1694-702.
Score: 0.006
-
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
Score: 0.004
-
Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999 Apr; 143(2):285-97.
Score: 0.003